Aardvark Therapeutics, Inc.
AARD
$6.41
-$0.16-2.44%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -21.50% | 33.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -32.85% | 20.10% | |||
| Operating Income | 32.85% | -20.10% | |||
| Income Before Tax | 33.36% | -22.67% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 33.36% | -22.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 33.36% | -22.67% | |||
| EBIT | 32.85% | -20.10% | |||
| EBITDA | 32.87% | -20.11% | |||
| EPS Basic | 33.44% | -22.48% | |||
| Normalized Basic EPS | 33.39% | -22.54% | |||
| EPS Diluted | 33.44% | -22.48% | |||
| Normalized Diluted EPS | 33.39% | -22.54% | |||
| Average Basic Shares Outstanding | 0.14% | 0.15% | |||
| Average Diluted Shares Outstanding | 0.14% | 0.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||